BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 14623056)

  • 1. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
    van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
    Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
    van Beek E; Löwik C; Karperien M; Papapoulos S
    Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption.
    Fisher JE; Rosenberg E; Santora AC; Reszka AA
    Calcif Tissue Int; 2013 Jun; 92(6):531-8. PubMed ID: 23435531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
    Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
    J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
    Oizumi T; Funayama H; Yamaguchi K; Yokoyama M; Takahashi H; Yamamoto M; Kuroishi T; Kumamoto H; Sasaki K; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 May; 68(5):1043-54. PubMed ID: 20156665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
    Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.